Finally, tumour-derived CAF exosomes carrying miR-92a-3p and other effectors induce cross-resistance to 5-FU and oxaliplatin in both HER2-negative and -positive cells, biologically masking any HER2-specific contribution at the population level (Hu et al., 2019). Here, ERBB2 is linked to neoplasm.